• BV6: A Causal Assay Framework for IAP Biology

  2026-08-25

  BV6 is an IAP antagonist that helps researchers interrogate apoptosis, treatment sensitization, and disease-model responses. This guide adds a distinct assay-interpretation framework informed by mitochondrial apoptosis research, separating pathway engagement from phenotypic rescue.

• EdU Imaging Kits (Cy3) for Organoid Studies

  2026-08-25

  EdU Imaging Kits (Cy3) combine denaturation-free click chemistry with bright Cy3 readouts for quantifying S-phase DNA synthesis in cells and patient-derived organoids. The workflow is especially useful for testing drug effects in cancer-associated fibroblast–tumor models while preserving morphology and downstream antigen accessibility.

• Cell Counting Kit-8 for Wound Hydrogel Research

  2026-08-24

  See how CCK-8 converts viable-cell metabolism into a practical readout for evaluating regenerative hydrogels, photothermal treatments, and biomaterial safety. This workflow emphasizes controls that separate true cytotoxicity from optical interference, heat stress, and three-dimensional matrix effects.

• Berberine, Tuft Cells, and Estrogen-Deficient Bone Loss

  2026-08-24

  The reference study identifies a gut–bone axis mechanism in which berberine increases intestinal butyrate, activates GPR41-associated signaling, and expands tuft cells to improve barrier integrity and osteoimmune balance. Its ovariectomy, microbiome, immune, genetic, and organoid experiments provide a mechanistic framework for investigating postmenopausal bone loss, while remaining preclinical.

• MAPK10–KRT16 Axis in NSCLC Metastasis

  2026-08-23

  The reference study identifies MAPK10 as a metastasis-suppressing kinase that phosphorylates KRT16 at Ser356 and Ser397, enabling RNF213-mediated ubiquitination and proteasomal degradation. Its integrated cellular, animal, and clinical evidence positions the MAPK10/KRT16/RNF213 axis as a mechanistic framework for studying NSCLC dissemination and as a candidate prognostic pathway.

• IWP-2 Workflow for Wnt Signaling Assays

  2026-08-22

  Build more informative Wnt pathway experiments with IWP-2, from soluble stock preparation through proliferation, apoptosis, and high-content morphology readouts. This workflow connects PORCN inhibition with the morphology-first strategy of a cardiomyocyte profiling study while clearly separating established product data from exploratory applications.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-08-22

  The reference study identifies CD44 as a functional metabolic dependency of IDH-mutant leukemia, linking adhesion signaling to pentose phosphate pathway activity, NADPH production, and sustained R-2HG synthesis. Its isogenic CRISPR-based design supports combination strategies that pair mutant-IDH inhibition with CD44-directed interventions while highlighting important questions about disease heterogeneity and therapeutic selectivity.

• Tamoxifen Workflows for CreER and Cancer Research

  2026-08-21

  Tamoxifen combines selective estrogen receptor modulation with practical utility as a temporal trigger for CreER-mediated gene knockout. This guide connects controlled gene deletion workflows with the mitochondrial iron findings of a recent PINK1 colorectal cancer study, while emphasizing formulation, controls, and troubleshooting.

• Pyridostigmine, α7nAChR, and Placental Necroptosis

  2026-08-20

  The reference study identifies placental necroptosis as a modifiable component of preeclampsia-like pathology and links its suppression to enhanced non-neuronal cholinergic signaling. Using pyridostigmine, α-bungarotoxin, necrostatin-1, a reduced uterine perfusion pressure model, and hypoxic trophoblast cultures, the authors provide pharmacological evidence that α7 nicotinic acetylcholine receptor signaling may connect cholinergic activity with placental inflammation, oxidative stress, and trophoblast dysfunction.

• Tetrandrine: Reproducible Assay Workflows

  2026-08-20

  This scenario-driven guide explains how Tetrandrine (SKU N1798) can be integrated into cell viability, proliferation, cytotoxicity, and ion channel modulation studies. It covers solvent compatibility, protocol controls, interpretation limits, and practical selection between ready-to-use and solid formats.

• Hydrocortisone as a Variable in EMT Splicing Assays

  2026-08-19

  Hydrocortisone is more than a glucocorticoid hormone in breast cancer culture systems: it can be a critical media variable when studying EMT-associated RNA splicing. This guide connects the CLSTN1 exon 11 study to practical controls, formulation, and assay design decisions.

• BATF2–ATF3 Axis in Disc Degeneration

  2026-08-19

  The reference study identifies BATF2 as an upstream regulator of ATF3 stability and links this axis to mitochondrial redox disruption, nucleus pulposus cell apoptosis, and extracellular matrix degradation in intervertebral disc degeneration. Its perturbation-based design suggests that BATF2–ATF3 signaling is more than a disease-associated marker and may provide a mechanistically testable target for future IVDD research.

• Grazoprevir/Elbasvir Therapy for HCV

  2026-08-18

  The reference review explains the translational rationale for pairing the NS3/4A protease inhibitor grazoprevir with the NS5A inhibitor elbasvir in an interferon-free regimen. It synthesizes clinical and real-world evidence showing high virologic response across important patient groups while emphasizing genotype, baseline resistance, treatment history, fibrosis, and comorbidities as determinants of regimen selection.

• Palbociclib (PD0332991) Isethionate Guide

  2026-08-18

  A scenario-driven guide to using Palbociclib (PD0332991) Isethionate, SKU A8335, in cell proliferation, viability, and cytotoxicity workflows. It connects CDK4/6 biology with practical choices in dosing, formulation, controls, interpretation, and vendor selection.

• Ivermectin Workflows for Parasitology Research

  2026-08-17

  Ivermectin supports controlled parasite assays, formulation checks, and mechanism-oriented screening when solvent, temperature, and exposure time are managed carefully. This workflow also shows how a recent Gasdermin C study can sharpen assay design without overstating evidence for oncology applications.

8549 records 1/570 page Next 12345 下5页 Last page